Business · Companies · 12 hrs ago

Zambon targets more than €1 billion in revenue by 2030

Zambon targets more than €1 billion in revenue by 2030

Italian pharmaceutical group Zambon is aiming to pass €1 billion in revenue by 2030, up from €843 million in 2025.

The company, which marks its 120th anniversary this year, operates in 87 countries and has more than 2,770 employees.

Its 2026–2030 plan includes about €750 million in investment in research, facilities, technology and acquisitions.

Zambon is looking for medium-to-large biotech acquisitions in Europe and the United States, focused on rare diseases and the central nervous system.

It has reviewed 378 biotech companies over three years and reached due diligence with 16.

A possible US launch of an inhaled antibiotic to help prevent lung infections in people with a rare condition could add to growth, if approved by the FDA.

Zambon says it is working toward filing an authorization application by the end of 2027.

1 source

Related

What people are saying

Elena ZambonZambon president
We have looked at 378 biotech companies over the last three years, and we reached due diligence with 16.
via Corriere della Sera
We are looking for medium-to-large acquisitions in rare diseases and the central nervous system, in Europe and the US.
via Corriere della Sera
How do I see this company in 2030? Increasingly international, strengthened in its three areas, and grown particularly in innovative therapies.
via Corriere della Sera